Intelligence · Clinical Pipeline
Alnylam Netherlands Pipeline
All ClinicalTrials.gov programs at Alnylam Netherlands — phase, modality, and trial IDs.
- Programs
- 21
Quick answer
Alnylam Netherlands has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran
Alnylam Netherlands B.V.
High cardiovascular risk, Established cardiovascular disease, Hypertension
1 trial -
0.9% Sodium chloride, Amvuttra 25 mg solution for injection in pre-filled syringe
Alnylam Netherlands B.V.
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
1 trial -
ALN-TTRSC04, Amvuttra 25 mg solution for injection in pre-filled syringe
Alnylam Netherlands B.V.
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
1 trial -
Amvuttra 25 mg solution for injection in pre-filled syringe
Alnylam Netherlands B.V.
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
1 trial -
Amvuttra 25 mg solution for injection in pre-filled syringe, Onpattro 2 mg/mL concentrate for solution for infusion.
Alnylam Netherlands B.V.
Hereditary Transthyretin Amyloidosis
1 trial -
Givosiran
Alnylam Netherlands B.V.
Acute Hepatic Porphyria
1 trial -
Lumasiran
Alnylam Netherlands B.V.
Primary Hyperoxaluria
1 trial -
Lumasiran
Alnylam Netherlands B.V.
Primary Hyperoxaluria Type 1
1 trial -
Nucresiran
Alnylam Netherlands B.V.
Transthyretin Amyloidosis With Cardiomyopathy
1 trial -
Nucresiran
Alnylam Netherlands B.V.
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
1 trial -
Onpattro 2 mg/mL concentrate for solution for infusion., Sodium Chloride Intravenous Infusion BP 0.9% w/v
Alnylam Netherlands B.V.
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
1 trial -
Patisiran
Alnylam Netherlands B.V.
Amyloidosis, Hereditary
1 trial -
Patisiran
Alnylam Netherlands B.V.
Amyloidosis
1 trial -
Patisiran
Alnylam Netherlands B.V.
Amyloidosis, Familial
1 trial -
Placebo
Alnylam Netherlands B.V.
Primary Hyperoxaluria Type 1 (PH1)
1 trial -
Placebo
Alnylam Netherlands B.V.
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
1 trial -
Placebo for Nucresiran, ALN-TTRSC04
Alnylam Netherlands B.V.
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
1 trial -
Revusiran (ALN-TTRSC)
Alnylam Netherlands B.V.
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
1 trial -
Vutrisiran
Alnylam Netherlands B.V.
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
2 trials -
Zilebesiran
Alnylam Netherlands B.V.
High Risk Cardiovascular Disease
1 trial -
patisiran (ALN-TTR02)
Alnylam Netherlands B.V.
TTR-mediated Amyloidosis
1 trial
Frequently asked questions
How many pipeline programs does Alnylam Netherlands have?
21 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs